D-1046-2019 Class II Terminated

Recalled by AVKARE Inc. — Pulaski, TN

FDA drug recall D-1046-2019 was initiated by AVKARE Inc. on Mar 5, 2019 and is designated Class II. Reason for recall: CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified The recall status is terminated (terminated Dec 7, 2020).

Recall details

Product Type
Drugs
Report Date
Mar 27, 2019
Initiation Date
Mar 5, 2019
Termination Date
Dec 7, 2020
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 50 Tablets (5x10) Unit Dose boxes, Rx Only Manufactured for: AvKARE Inc. Pulaski, TN 38478 --- NDC 50268-514-15

Reason for recall

CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified

Distribution pattern

Nationwide.

Code information

Lot: 19326 Exp. 03/31/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1046-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1046-2019. Report a data issue: hello@regdatalab.com.